$PFSA

HRT FINANCIAL LP sold $38K of PFSA

HRT FINANCIAL LP sold 42,411 shares of Profusa, Inc. (PFSA) at $0.89 on 2026-08-13.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 14, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFSA
Neutral
medium confidence
Mentioned
$PFSA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

A 10% owner open-market sale can slightly influence sentiment, but the filing does not include any new company-specific catalysts like earnings, guidance, contracts, or regulatory actions.

02

Market read

Traders may monitor PFSA for follow-on selling signals, but this disclosure alone is unlikely to change valuation drivers.

03

What to watch

The sale size is modest and Form 4 transactions often reflect diversification, liquidity needs, or pre-planned personal actions not tied to company outlook.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-14, transaction dated 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA).

Company-level read

Ticker impact

$PFSANeutralMedium confidence
Context

Profusa, Inc. (PFSA) disclosed via Form 4 that HRT Financial LP sold 42,411 shares at $0.8880 on 2026-08-13.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around the filing.

Evidence & confidence

Form 4 sales are common and this filing provides no new operational or financial guidance, only transaction details and post-sale holdings.

Market effects

No clear sector read-through from a single small Form 4 sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as bearish.

Key entities

  • Profusa, Inc.

    Company whose shares were sold; ticker PFSA.

  • HRT Financial LP

    Reporter and 10% owner who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.